It’s worth remembering once you convert a surgeon to your product, it generally becomes a very stable source of re-occurring revenue as they become more familiar and confident with the device.
iTrack Advance is the best device for MIGS on the market today. This is clearly evident with the rate of the Sales growth. As they capture more of the US market share, it will pave an easier entry into other markets.
The product moat is what has me invested, the margin is good so as long the management team can practise good monetary discipline this is on it ways to CF+ business which will warrant more investment from the market, which in turn will help develop 2RT.
I am not a patent expert but for sure the current IP the company holds has to be worth more than the current EV. That’s why I believe it’s undervalued.
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-272
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
0.005(3.33%) |
Mkt cap ! $35.50M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 15.5¢ | 15.5¢ | $13.41K | 86.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 581087 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 150000 | 2 |
View Market Depth
| Last trade - 13.10pm 15/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |